menu
    • menu
    [{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Cheplapharm Arzneimittel Gmbh

    Menu

    Cheplapharm Arzneimittel Gmbh

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            World Vaccine Conference
                            Not Confirmed

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : $825.9 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Cheplapharm Places Notes in A Volume of €750m in Challenging Market Environment

                            Details : The proceeds from the new bonds will be used to finance the acquisition of the worldwide commercial rights for Zyprexa (olanzapine), an antipsychotic medication, from Eli Lilly and Company.

                            Product Name : Zyprexa

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 28, 2023

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : $825.9 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth